Caroline Seymour

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

The addition of liver transplantation to chemotherapy led to improved overall survival at 5 years in patients with definitively unresectable colorectal cancer metastasis in the liver.

Olaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

The phase 3 EV-302/KEYNOTE-A39 trial, which includes prespecified subgroup analyses, revealed favorable outcomes compared with chemotherapy. The findings pertain to patients with previously untreated locally advanced or metastatic urothelial carcinoma.

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant and D-VRd consolidation and daratumumab/lenalidomide maintenance significantly prolonged progression-free survival.

Duration of ibrutinib and venetoclax, as determined by the patient’s minimal residual disease, improved survival in patients with treatment-naïve chronic lymphocytic leukemia.

Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Early trials are exploring the benefit of chimeric antigen receptor T-cell therapy in advanced renal cell carcinoma.

Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Tisotumab vedotin-tftv improved survival in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

The BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors is advancing to phase 1b following encouraging preliminary results.

Responses to BI 764532 in patient siwth DLL3-positive small cell lung cancer appear to be durable and are ongoing in the dose optimization portion of a phase 1 study.

Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

REGN5459 led to positive responses among patients with multiple myeloma, according to findings from a first-in-human phase 1/2 trial.

In the phase 2 KEYNOTE-942 trial, the 18-month distant metastasis-free survival rate was 91.8% with mRNA-4157 plus pembrolizumab vs 76.8% with pembrolizumab alone.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

News results from. the phase 3 AEGEAN trial further support the use of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant setting for patients with non–small cell lung cancer.